Literature DB >> 22815109

Patient classification and hospital costs of care for acute myocardial infarction in nine European countries.

Unto Häkkinen1, Pietro Chiarello, Francesc Cots, Mikko Peltola, Hanna Rättö.   

Abstract

This study contributes to the literature on the performance of diagnosis-related groups (DRGs) for acute myocardial infarction (AMI) patients by evaluating in nine countries the factors--in addition to DRGs--that affect costs or length of stay and comparing the variation that can be explained with or without DRGs. We evaluate whether the existing DRGs for AMI patients would benefit from additional patient-related and treatment-related factors that are found in administrative data across countries. In most countries, the set of patient and quality variables performed better than the DRG variables. Our results suggest that DRG systems in all countries could be improved by including additional explanatory factors or by refining the existing DRGs. Our results suggest that for AMI and possibly for other related episodes, a refinement of DRGs to include information on patient severity, procedures and levels of complications could improve the ability of DRGs to explain resource use. It seems possible to improve DRG-like hospital payment systems through the inclusion of episode-specific variables.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22815109     DOI: 10.1002/hec.2840

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  9 in total

1.  Explaining length of stay variation of episodes of care in the Netherlands.

Authors:  Siok Swan Tan; Leona Hakkaart-van Roijen; B Martin van Ineveld; W Ken Redekop
Journal:  Eur J Health Econ       Date:  2012-10-21

2.  Treatment costs of acute myocardial infarction in the Netherlands.

Authors:  R R Soekhlal; L T Burgers; W K Redekop; S S Tan
Journal:  Neth Heart J       Date:  2013-05       Impact factor: 2.380

3.  National trends in hospital length of stay for acute myocardial infarction in China.

Authors:  Qian Li; Zhenqiu Lin; Frederick A Masoudi; Jing Li; Xi Li; Sonia Hernández-Díaz; Sudhakar V Nuti; Lingling Li; Qing Wang; John A Spertus; Frank B Hu; Harlan M Krumholz; Lixin Jiang
Journal:  BMC Cardiovasc Disord       Date:  2015-01-20       Impact factor: 2.298

Review 4.  Patient-level costs of major cardiovascular conditions: a review of the international literature.

Authors:  Gina Nicholson; Shravanthi R Gandra; Ronald J Halbert; Akshara Richhariya; Robert J Nordyke
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-21

5.  It probably worked: a Bayesian approach to evaluating the introduction of activity-based hospital payment in Israel.

Authors:  Ruth Waitzberg; Martin Siegel; Wilm Quentin; Reinhard Busse; Dan Greenberg
Journal:  Isr J Health Policy Res       Date:  2022-02-15

6.  Acute myocardial infarction and diagnosis-related groups: patient classification and hospital reimbursement in 11 European countries.

Authors:  Wilm Quentin; Hanna Rätto; Mikko Peltola; Reinhard Busse; Unto Häkkinen
Journal:  Eur Heart J       Date:  2013-01-30       Impact factor: 29.983

7.  Current ICD10 codes are insufficient to clearly distinguish acute myocardial infarction type: a descriptive study.

Authors:  Roxana Alexandrescu; Alex Bottle; Brian Jarman; Paul Aylin
Journal:  BMC Health Serv Res       Date:  2013-11-07       Impact factor: 2.655

Review 8.  Capturing patients' needs in casemix: a systematic literature review on the value of adding functioning information in reimbursement systems.

Authors:  Maren Hopfe; Gerold Stucki; Ric Marshall; Conal D Twomey; T Bedirhan Üstün; Birgit Prodinger
Journal:  BMC Health Serv Res       Date:  2016-02-03       Impact factor: 2.655

9.  Economic valuation of informal care provided to people after a myocardial infarction in France.

Authors:  Hugo Rabier; Hassan Serrier; Anne-Marie Schott; Nathan Mewton; Michel Ovize; Norbert Nighoghossian; Antoine Duclos; Cyrille Colin
Journal:  BMC Health Serv Res       Date:  2019-10-28       Impact factor: 2.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.